Skip to content
Screener

Haemonetics HAE Operating Cash Flow

Operating Cash Flow at other companies

Abbott logo
AbbottABT
$2.49B+21.5%
TFX
TeleflexTFX
$91.9M+348%
Boston Scientific logo
Boston ScientificBSX
$348M-35.7%
Medtronic logo
MedtronicMDT
$2.57B+1.8%
LivaNova logo
LivaNovaLIVN
$66.59M+5.8%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$970K-45.5%

Other financials

Income statement

See full
Revenue$339.4M+5.6%
Gross profit$202.8M+5.5%
Operating income$57.5M+6.7%
Net income$33.0M-3.0%
EPS (diluted)$0.72+2.9%

Balance sheet

See full
Cash & equivalents$223.4M-23.7%
Total debt$1.2B-4.1%
Total equity$837.1M-5.1%
Total assets$2.4B-3.9%

Cash flow

See full
CapEx$7.9M+111%
Free cash flow$44.4M+226%

Valuation

See full
Market cap$3.87B+6.3%
Enterprise value$4.82B+5.4%
P/E25.7×-10.5×
P/S2.9×+0.2×

Profitability

See full
Gross margin59%+2.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin21.5%+7.5pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.4×0.0×
Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:09 AM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000313143-26-000120
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025
Change in prepaid income taxes6,1013,346
Change in other assets and other liabilities(12,783)(17,785)
Change in accounts payable and accrued expenses(12,615)(47,896)
Net cash provided by operating activities52,32317,395
Cash Flows from Investing Activities:
Capital expenditures(7,906)(3,754)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment(5,565)(11,460)
Proceeds from sale of property, plant and equipment237297

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's operating cash flow?
Haemonetics (HAE) reported operating cash flow of $52.32M in Q2 2026.
How has Haemonetics's operating cash flow changed year-over-year?
Haemonetics's operating cash flow increased by 200.8% year-over-year, from $17.4M to $52.32M.
What is the long-term trend for Haemonetics's operating cash flow?
Over 4 years (2022 to 2026), Haemonetics's operating cash flow has grown at a 14.2% compound annual growth rate (CAGR), from $172.26M to $293.22M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Haemonetics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude